Table 1.
Baseline characteristics of the study population before procedure.
| Variables | Values (Mean (SD) [Min, Max]) | |
|---|---|---|
| Age, years | 56.0 (7.76) [33.0, 72.0] | |
| Sex | ||
| Male | n = 34 (46.5%) | |
| Female | n = 39 (53.5%) | |
| Waist circumference, cm | 115.5 (10.7) [95, 129] | |
| Height, cm | 168.6 (8.6) [150, 186] | |
| Weight, kg | 97.6 (17.7) [60.0, 134] | |
| BMI (kg/m2) | 34.3 (5.6) [22.1, 51.2] | |
| Drug regimen | Before procedure | 48 months after procedure |
| Number of antihypertensive drugs | 5.97 (1.1) [4–11] | 5.45 (2.2) [3–11] |
| Total number of pills | 7.33 (2.44) [2–14] | 6.92 (3.37) [2–16] |
| Prescribed drug classes | ||
| ACE-I/ARB | 73 (100%) | 47 (95.9%) |
| Diuretics | 67 (91.8%) | 39 (79.6%) |
| Calcium channel blockers | 63 (86.3%) | 42 (85.7%) |
| Beta blockers | 66 (90.4%) | 27 (55.1%) |
| Mineral receptor antagonists | 48 (65.7%) | 43 (87.8%) |
| Centrally acting agents | 57 (78.1%) | 24 (49.0%) |
| Alpha blockers | 45 (61.6%) | 32 (65.3%) |
| Oral antidiabetic drugs * | 29 (39.7%) | 18 (36,7%) |
| Oral anticoagulants | 5 (6.8%) | 8 (16.3%) |
| Antiplatelet drugs | 21 (28.7%) | 23 (46.9%) |
| Statins | 32 (44.4%) | 24 (48%) |
Values are expressed as n, median (interquartile range), mean (SD) [min;max] or n (%), unless otherwise stated. ACE: angiotensin-converting enzyme; ARB: angiotensin-receptor blocker; BMI: body mass index; n: number of subjects with available data. * Biguanides, sulphonylureas.